Respiratory Infections

A group of over 60 scientists participated in a communication to the federal agency to advocate for measuring these cells in COVID-19 vaccine trials.

Pediatric intensive care unit (PICU) hospitalizations were 41% lower than expected during the outbreak of COVID-19.

Investigators used procalcitonin (PCT) levels to guide antibiotic recommendations in pediatric intensive care units. PCT-guided antibiotic stewardship decreased the number of antibiotic days without leading to therapy failure.

What are the clinical characteristics of children under 1 year old who are hospitalized with COVID-19 infection?

One study, presented at the Critical Care Congress, found that initiating remdesivir (Veklury) earlier did not significantly reduce the recovery time of hospitalized COVID-19 patients.

An analysis of readmissions after hospitalization with community-acquired pneumonia (CAP) in France found that few readmissions were avoidable, supporting criticism that the measure may lead to unfair penalties under pay-for-performance programs.

Antimicrobial stewardship efforts, such as education for healthcare providers, significantly decreased community-acquired pneumonia antibiotic prescriptions in COVID-19 patients.

Selecting initial antibiotic for ventilator-associated pneumonia from Gram staining and resistance records could reduce broad spectrum agents.

Patients scheduled for primary care appointments were more likely to get an influenza vaccine if they received a text message the night before indicating one was reserved for them, a new study shows.

Though many monoclonal antibodies were paused after demonstrated to be insufficient against the BA.1 Omicron subvariant, they may be more effective against BA.2.

A systematic review of clinical trials found a high probability that fluvoxamine prevented COVID-19 hospitalizations in outpatient settings.

The risks of deep vein thrombosis, pulmonary embolism, and bleeding events were increased at 3 or more months after COVID-19 infection.

After the US Food and Drug Administration (FDA) fully authorized the Pfizer-BioNTech mRNA vaccine, series-completing second doses increased substantially. However, first vaccine doses were actually administered at lower rates after the approval.

Bedaquiline-resistant tuberculosis is characterized in South Africa, where it has not been reserved as last resource for drug-resistant TB.

Being displaced by war is causing a disruption in treatment and long-term health care for Ukrainians. And it is likely, the situation will become more dire as the country’s public infrastructure worsens.

Notoriously slow to implement new practices, most hospitals rapidly updated their standard treatment procedures during the COVID-19 pandemic.

Children under 5 became infected with the Omicron variant 6-8 times more frequently than young children who contracted Delta. However, Delta COVID-19 infections were more severe than Omicron.

Despite lower comorbidity risk scores than Black or White COVID-19 patients, Mississippi’s Indigenous populations had significantly higher in-hospital mortality rates.

One day after the FDA approved second booster shots for certain vulnerable populations, the National Institute of Health (NIH) announced they have begun enrolling adult US participants in a phase 2 clinical trial to evaluate a second COVID-19 booster dose.

2 doses of the Pfizer-BioNTech vaccine reduced Omicron hospitalizations by 68% in children 5-11 and by 40% in adolescents 12-18 years old.

“Together these 2 diseases create a perfect storm”: Black people with cancer were more likely to have severe or fatal COVID-19 disease.

The World Health Organization updated its guidelines for the treatment of nonsevere tuberculosis in children after a study showed a four-month duration was noninferior to six months.

The coronavirus pandemic caused the first global recorded decline in human life expectancy.

The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.

A matched cohort study found COVID-19 infection increased the risk of new type 2 diabetes diagnosis. Compared to patients with acute upper respiratory tract infections, COVID-19 patients were 28% more likely to develop diabetes.